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I
n a recent issue of Kidney International, Dr. 
Sigrid Harendza’s diary described how an 
unprecedented number of patients with 
hemolytic uremic syndrome (HUS) swamped 
hospitals in northern Germany in May. As neph-
rologists we are familiar with patients suff ering 
from HUS; however, HUS is a rather rare event 
in clinical practice, particularly in adults. Most 
cases in adults are of noninfectious etiology and 
due to drug eff ects or other underlying diseases. 
By contrast, infection with Shiga toxin-producing 
Escherichia coli, usually associated with prodromal 
diarrhea, is the primary cause of HUS in children.
HUS caused by enteric infection is statutorily 
notifi able in Germany, and the national database 
on notifi able infectious diseases is hosted by the 
Robert Koch Institute, the federal-level public-
health institute. Since 2001, the Robert Koch Insti-
tute received between 44 and 118 reports of HUS 
cases per year, primarily pediatric patients. In May 
2011, the situation changed dramatically.
Epidemic profile of the outbreak
An outbreak of Shiga toxin-producing E. coli 
O104:H4 infection started in early May in Ger-
many. Th e number of HUS cases peaked at 65 
on 21 May—as many as would be expected for 
a whole year in Germany. Th e outbreak declined 
aft erward, with few cases of HUS occurring aft er 
16 June (Figure 1).
As of 25 July, almost 4000 symptomatic cases, 
including 50 deaths, had been attributed to the 
outbreak, of which 732 were confi rmed cases and 
120 were suspected cases of HUS. In a preliminary 
report, 89% of these patients were older than 18 
years (median age, 43 years), and women were 
overrepresented.1 Th e outbreak occurred primarily 
in northern Germany.1 Cases have been reported 
throughout Germany and from more than 15 other 
countries; most had a history of travel to northern 
Germany. The outbreak exhibits novel epide-
miological, clinical, and microbiological features. 
Prominent among them are the unprecedented pro-
portion and total number of HUS cases, and that 
the majority of HUS patients were adults. Data on 
prospectively followed patients in this outbreak and 
German notifi cation data indicate that about 20% 
of diarrheal Shiga toxin-producing E. coli O104:H4 
patients in this outbreak developed HUS.1 Th is pro-
portion is higher than those in previous reports on 
large outbreaks all over the world and suggests a 
high virulence of the outbreak strain.
Character of the E. coli strain associated 
with the outbreak
Th e outbreak strain is unusual in several ways. It 
has an enteroaggregative E. coli genomic back-
ground, with a bacteriophage that carries the Shiga 
toxin 2 gene integrated into the chromosome. In 
addition, two plasmids (circular, self-replicating 
DNA molecules that exist extrachromosomally) 
carry aggregative adhesion fi mbrial operons as 
well as antibiotic resistance information including 
extended-spectrum β-lactamases and trimetho-
prim/sulfamethoxazole. Th is genetic combination 
gives rise to a hybrid pathogen that has the inti-
mate intestinal adherence of enteroaggregative E. 
coli with the toxigenicity of enterohemorrhagic E. 
coli (EHEC) and the added complication of anti-
biotic resistance.
Th e outbreak strain belongs to the HUSEC041 
(O104:H4, ST678) complex. Another member of 
this complex was fi rst isolated from a child with 
HUS in Cologne, Germany, in September 2001 
and was extensively characterized.2 No other 
HUSEC041 complex isolates were detected from 
the more than 700 HUS isolates during the last 15 
years until the current outbreak in Germany. We 
are unaware of any additional outbreaks caused 
by this pathogen group in other parts of the 
world before the onset of the German outbreak. 
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In May–June 2011 northern Germany suﬀ ered from 
one of the worst outbreaks of EHEC infection, with 
a high incidence of severe HUS. About 4000 people 
were infected and at least 46 died. Dr. Harendza, a 
staﬀ  nephrologist at the Hamburg University hospital, 
recorded the events in a daily diary, which gives a vivid 
account of how the epidemic ﬂ ooded the hospital and 
strained its dialysis and plasmapheresis abilities, both in 
terms of technical capability and human resources.
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From this we can conclude that this outbreak 
strain must be extremely rare as a cause of HUS 
and diarrhea.
Much is still unknown about the HUSEC041 
complex strains. Th e pathogens have not yet been 
detected in animal groups, and no other evidence 
has been collected to suggest that the pathogen is 
of zoonotic origin. Th is could imply that humans 
are the sole carriers of O104:H4. Little is known 
about the persistence of EHEC O104:H4 in both 
the human and nonhuman environments. Th e 
infectious dose is also unknown, though we can 
speculate that it is low on the basis of the observed 
high acid resistance. The status of immunity 
within the human population may also be low, 
as this strain appears to be a newcomer to the 
pool of circulating pathogens. Th e geographic 
spread of this strain, as well as the extent of its 
existence within asymptomatic human carriers, 
is still unknown. But this knowledge would be of 
high importance in our globally connected world.
Recommendations of German and European 
authorities
On 10 June, federal public-health and food safety 
authorities in Germany advised consumers not 
to eat raw sprouts. The advice was based on 
analytical epidemiological studies and prelimi-
nary food-tracing results. In June, an outbreak 
of EHEC O104:H4 occurred in the southwest 
of France, and sprouts were suspected as the 
vehicle of infection. Despite isolation of the 
identical outbreak strain, patients from France 
reported having had no contact with products 
from northern Germany. Th e public advice in 
Germany was tailored to fenugreek sprouts and 
seeds on 21 July. Th e European Commission 
suspended the importation of fenugreek seeds 
and additional seeds from Egypt until 31 Oct-
ober 2011. Th e Commission decided to with-
draw from the market and destroy all batches 
of fenugreek seeds imported between 2009 and 
2011 from Egypt. But to the best of our knowl-
edge, EHEC O104:H4 has not been isolated from 
fenugreek seeds or sprouts until now.
Clinical course of hemolytic uremic syndrome in 
this outbreak
Most patients were admitted with bloody diar-
rhea, followed by deteriorating kidney function, 
hemolysis, and thrombocytopenia in about 
50% within a few days. In contrast to previous 
descriptions, more than half of the HUS patients 
exhibited particular neurological symptoms. 
Loss of the ability to control the mind horri-
fi ed those young patients with an unremark-
able medical history. Oft en, focal or generalized 
epileptic seizure accompanied the disease, but 
fortunately, computed tomographic or magnetic 
resonance scans revealed only a few cases with 
focal infarctions, and most cerebral diagnos-
tic images remained almost normal. In certain 
cases, neurological symptoms preceded the clas-
sical HUS. About 10% of the HUS patients with 
life-threatening complications, including E. coli 
sepsis or necrotizing enteritis, were admitted to 
an intensive care unit. Th e severity of the disease 
urged a specifi c therapeutic approach.
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Figure 1 | Epidemic curve of an outbreak of gastroenteritis and hemolytic uremic syndrome caused by Shiga 
toxin-producing Escherichia coli O104:H4 in Germany. The numbers of notified cases of enterohemorrhagic E. 
coli (EHEC)-associated gastroenteritis and of hemolytic uremic syndrome (HUS) are displayed by onset of diarrhea (if 
reported) during May and June 2011. 
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Although the clinical course and the patho-
physiology of the disease are well characterized, 
there is a lack of specifi c therapeutic evidence-
based options beyond optimal supportive 
treatment. At the beginning of the outbreak, 
an ad hoc committee of the German Society of 
Nephro logy recommended treating all HUS 
patients with renal or neurological and hema-
tological symptoms with plasmaphereses. Th e 
rationale behind this recommendation seems 
to be limited, as cell-bound Shiga toxin may not 
be eff ectively eliminated from the circulation 
by plasmaphereses. Profound clinical evidence 
is also lacking; a recent analysis concluded that 
plasmapheresis is a “promising” therapeutic 
option and not more.3 Just at the beginning of 
the outbreak, an article reported that treatment 
with eculizumab improved the clinical course 
dramatically in three pediatric patients within 
days.4 Eculizumab is a recombinant humanized 
monoclonal IgG2/4 antibody that specifi cally 
binds to the complement protein C5, inhibiting 
its cleavage by the C5 convertase, which prevents 
the generation of the terminal complement com-
plex C5b-9. Accordingly, the German Society of 
Nephrology extended the recommendation to 
include treatment of all patients who exhibited 
no short-term improvement aft er beginning plas-
maphereses with this antibody. Finally, a variety 
of patients have been treated with diff erent anti-
biotic regimens despite reports that antibiotics 
might worsen the course.5 At the beginning, only 
eculizumab-treated patients received antibiotics 
to prevent meningococcal infections, as well as 
patients with necrotizing enteritis or concomi-
tant systemic bacterial infection. However, on the 
basis of the specifi c potency of EHEC O104:H4, 
some centers liberalized the antibiotic treatment 
option to eliminate the causative agent earlier.
Conclusion
At the time of this writing, this outbreak seems to 
be over, and we can observe that the majority of 
patients survived the disease without any residual 
organ damage. However, in some patients kidney 
function did not normalize, and a few patients 
still suff er from neurological symptoms. To date, 
50 patients died. Despite this rather favorable 
outcome, this outbreak was characterized by 
the uncertainty of specifi c therapeutic options. 
Although not obtained in a randomized fashion, 
retrospective analyses of this outbreak will hope-
fully provide reasonable information allowing 
establishment of an evidence-based and appro-
priate therapeutic repertoire for patients suff ering 
from hemolytic uremic syndrome.
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